Blood Test Predicts Pregnancy Due Date

A small study based on circulating RNA in the blood of moms-to-be describes a technique that could be used to help predict who’s most at risk of preterm labor.

Written byKerry Grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ISTOCK, JACOBLUNDIn a study of 31 expectant mothers, researchers were able to accurately peg their due dates roughly half the time by sequencing nine types of circulating RNA in the blood. The test was about as reliable as using ultrasound, currently the go-to method of establishing a due date. The method, described today (June 7) in Science, also enabled the researchers to predict, in most cases, which of the high-risk pregnancies would end prematurely.

“Obviously the numbers [of participants] are very small but the results are very impressive,” Andrew Shennan, an obstetrics professor at St. Thomas’ Hospital in London who was not involved in the study, tells The Guardian. He adds that such a blood test would be especially useful in developing countries where ultrasound is not readily available.

The study to predict women’s due dates included expectant mothers in Denmark who submitted a blood sample each week throughout their pregnancies. The researchers zeroed in on nine transcripts known to originate in the placenta whose levels corresponded with pregnancy progression. Using these to predict the women’s due dates, the researchers got within 14 days 45 percent of the time. Ultrasound does the same 48 percent of the time, according ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies